Research volunteers workshop: report on workshop proceedings: discussion, conclusions and next steps by Morris, N et al.
R E S E A R C HVO L UN T E E R SWOR K S HO P
R E PO R T ON WOR K S HO PP ROC E E D I N G S :D I S C U S S I O N , CONC L U S I O N S A N D N E X T S T E P S
R e s e a r c h V o l u n t e e r sW o r k s h o p
J u n e 1 0 t h 2 0 1 1
U n i v e r s i t y C o l l e g e L o n d o n
R e p o r t o n W o r k s h o p P r o c e e d i n g s :
d i s c u s s i o n , c o n c l u s i o n s a n d n e x t s t e p s
R E PO R T ON WOR K S HO PP ROC E E D I N G S :D I S C U S S I O N , CONC L U S I O N S A N D N E X T S T E P S
CON T E N T S
Workshop Organisers / 4Acknowledgements / 5
E x e c u t i v e S umma r y / 6
C o n t e x t
About the Workshop / 13Participants / 14Agenda / 16
We l c ome / 1 9
R e s e a r c h R e p o r t s
Introduction / 21'Just Bodies?' / 22Treating Patients Using the Internet / 24Research Participant Engagement at the University of California, Irvine / 26Questions and DiscussionSustaining participation / 28Levels of patient participation / 28Improving feedback to participants / 28Practicalities of involving faculty and community / 29Ownership of research results / 29
T h e C o n t r i b u t i o n o f P a t i e n t G r o u p s a n d P P I
Introduction / 31The Role and Policies of the Independent Cancer Patients' Voice / 32Research Innovation Forum / 34Reflections on CERES (Consumers for Ethics in Research) / 36Questions and DiscussionDiversity of the patient community / 38Role and functions of patient groups / 38Is there a space for the voice of research participants? / 39
Go v e r nme n t , S p o n s o r s h i p a n d t h e P a r t i c i p a n t
Introduction / 41PPI at the National Cancer Research Institute / 42Research Governance and PPI­ the view from a large Trust / 44Questions and DiscussionImpact of patient involvement and related programmes / 46Regulatory matters / 46Returning to questions of impact / 47
R e f l e c t i o n s a n d E x p l o r a t i o n
Introduction / 49The Politics of Patient Participation / 50Reports from Break­Out Groups
A­ Does PPI as currently practised, affect the experience or level ofinvolvement of actual 'research participants'? / 52
B­ Are the people enrolled in a clinical study best (or most accurately)described as participants, collaborators, or research subjects? / 53
C­ Government policy plans to increase the proportion of patientstaking part in research. What are the implications of this for patientsand research participants? / 54
Final Workshop DiscussionWhat kind of regulation? / 56Practice and functions of the ethics committee system / 56Going beyond 'protection' / 57
C o n c l u s i o n s , R e c ommen d a t i o n s a n d N e x t S t e p s
Micro­level issues / 60Macro­level issues / 62Next Steps / 65
Glossary of Acronyms / 67
2WOR K S HO P O R G A N I S E R S
The Research Volunteers Workshop was organised by:
Dr Norma Morris­ Research Fellow at the Science and Technology StudiesDepartment, UCL. Her research interests range from university­governmentrelations to issues around human experimentation.
Dr Brian Balmer­ Reader in the Science and Technology StudiesDepartment, UCL. He has a broad interest in using historical and sociologicalapproaches to understanding science, expertise and science policy, and hasworked on the history and sociology of human experimentation in militaryresearch contexts. He is currently finishing a book on science and secrecyto be published by Ashgate.
Professor Jeremy Hebden­ Head of the Department of Medical Physics &Bioengineering and Director of the UCL Biomedical Optics ResearchLaboratory. His research interests include development of novel opticaltechniques for functioning imaging of the brain and breast.
3A C K NOW L E D G EM E N T S
The organisers would also like to thank:Shana Vijayan for her work as project managerNadia Robb for help and advice in planning and organisationStephen Mawdsley for help on the day
Funding for this project has been provided by the following organisations:
The Economic and Social Research CouncilUniversity College London
4E X E C U T I V E S UMMA R Y
The Research Volunteers Workshop provided the opportunity for a diversegroup of stakeholders in biomedical research to come together and discussthe role of the research participants (or ‘subjects’) in contemporary researchpractice. Those invited included researchers, patients, patient groups, funders,managers and policy­makers. The objective was to try and assess practicesin order to improve both the experience of the participants, and the qualityof research findings. Well­managed volunteer involvement has the potential togenerate research results that are better honed to public needs, and ofmore reliable quality. The findings of the workshop have wide­rangingimplications for policy.
In order to take full advantage of the wide range of perspectives, thepresentations were brief, and the focus of the day was on networking anddiscussion, as means to greater understanding between the different parties,increased collaboration and to form concrete recommendations for improvingcurrent practices.
R e s e a r c h R e p o r t s
The workshop began with presentations by researchers in both biomedicaland social sciences and participating research volunteers. They gave someperspectives from the field about their experiences of working in partnershipin research. The session was chaired by Professor Hugh Middleton, School ofSociology and Social Policy, Nottingham and NHS Consultant Psychiatrist,who introduced the short presentations.
The first presentation was from the organisers, about the study that wasboth the basis of an extended research project, and the origin of theworkshop itself. The presenters were a group made up of a researcher fromthe Science and Technology Studies department, UCL, Dr Morris withProfessor Jeremy Hebden who is developing new optical imaging techniquesfor the breast, and one of the research participants who had helped with thedevelopment of this new technology, Ms Fullerton. Together they gave anoverview of what they had discovered about the potential for participants’roles in the research process, and the ways in which good workingrelationships were developed. Dr Leff and Mr Jarvis, gave a presentation oftheir innovative work taking research (and treatment) out of the lab, andonto the internet, and their observations of changing roles. Finally, Dr Terangave an overview of some of the aims and new practices being developed atthe Institute for Clinical and Translational Science, University of California
5Irvine to promote a more reciprocal relationship between researchers andcommunities.
The discussion that followed raised questions about how to develop andmaintain successful relationships between researchers and participants,particularly over longer­term projects, and how both communication andfunding practices might affect these. There was also some discussion aboutthe accreditation and ownership of research results where participants hadbecome highly engaged in the research process.
T h e c o n t r i b u t i o n o f P a t i e n t G r o u p s a n d P P I
This session was chaired by Dr Louise Wood, Deputy Director, R&DDirectorate, at the Department of Health. The session aimed to examine howorganised groups, whether patient­ or researcher­led, may contribute to theresearch participant’s experience. Dr Morgan, and Mrs Wilcox gave apresentation of the campaigning activities of the ICPV­ Independent CancerPatients’ Voice group, which have included organising study days to promoteresearcher­patient/participant dialogue, and efforts to increase patient voiceat structural levels in research organisations. Dr Shawe, supported by Forummember Erika Narkiewicz, gave an overview of the creation of the newResearch and Innovation Forum that exists to give the local communities agreater role in organising and steering the research of the Margaret PykeCentre for Sexual and Reproductive Health. Finally Dr Pfeffer gave anoverview of her work with CERES (Consumers for Ethics in Research) acampaign group that had led the way in promoting participant empowerment,and good practice amongst researchers.
The session ended with debate on a number of issues including the diversityof the patient/research volunteer community, and consideration of how thatcould be best represented. There was also discussion of structuresembedded within research procedures that were inhibiting patient involvement,these included power relationships, but also rules of confidentiality whichmay leave participants unable to seek support from peer groups.
Go v e r nme n t , S p o n s o r s h i p a n d t h e P a r t i c i p a n t
This panel, also chaired by Dr Wood, explored the role of the majorinstitutional structures around research governance, regulation andsponsorship in shaping the research participant’s experience.
6The first presentation, given by Dr Jane Cope of the National CancerResearch Institute, gave an overview of how attitudes towards patientparticipation had changed during the course of her career and how differentpractices had evolved, particularly in relationship to governance. She drewattention to issues around assessing the level of regulation most beneficialto patients. The second presentation by Dr Susan Kerrison of the UCL/UCLHJoint Unit framed PPI within the context of the vast number and extremes ofscale of studies that take place in this organisation each year. Shehighlighted the diversity of roles that research participants play in these.
The ensuing discussion debated the role of PPI in various kinds of research,and research environments, what it might contribute, how it should beevaluated its impact assessed different situations. Specific areas identified foraction included the sharing of information, lack of regulatory attention tosocial and structural contexts affecting participation, and PPI in commercialtrials.
R e f l e c t i o n s a n d E x p l o r a t i o n
The afternoon session of the Workshop followed a less traditional formatthan the morning’s proceedings. It was designed to elicit the maximumcontribution from all the participants, and consisted of three main sections,each aiming in different ways to promote reflection and deeper explorationof the themes emerging from the morning’s presentations and discussions.
These three sections comprised:
1. Discussion in Break­out Groups
2. Afternoon Plenary address by Professor Stuart Blume on the socialand political context of clinical trials
3. Reports from the Break­out Groups and concluding plenary discussionsession
Both the plenary session and the Break­out Group reports raised issues thattranscended the frame of the individual clinical study. They stressed theimportance of understanding the meaning of medical research for potentialvolunteers and the range of roles that participants could play. Both exploredthe delicate balance between trust and regulatory safeguards, andweaknesses in current governance systems which concentrate too much on
7the early stages of studies (initial patient information and consent) andlacked systematic attention to trial management and social issues of concernto participants. In the global context as well as closer to home, the localpolitical economy of health shaped the choices available to potentialvolunteers, and could result in blurring of research and care. The finaldiscussion included recommendations for reviewing, with patient input, thekind of regulation needed; for evolution of Ethics Committees practices andphilosophy; and for recognising through regulatory systems thatpatient/participants needs went beyond ‘protection’, embracing issues such asinformation, access and appropriate research design.
Break­Out Groups
Each Group was assigned a topic for discussion, a broadly independentchairman, and someone with close knowledge of the particular area to startoff the discussion. The groups debated the questions for about an hour andthen drew together the main threads for report back to the plenary sessionafter the tea break. A note­taker was provided for each group to help in thisprocess.
The topics for discussion were as follows:
Group A: Does Patient and Public Involvement (PPI), as presently practised,affect the experience or level of involvement of actual ‘research participants’?Chair: Carolyn Morris (COMPASS User Involvement Group)Opening the discussion: MaryRose Tarpey (INVOLVE)
Group B: Are the people enrolled in a clinical study best (or most accurately)described as participants, collaborators or research subjects?Chair: Dr Brian Balmer (UCL)Opening the discussion: Dr Oonagh Corrigan (Associate Professor inSociology and Ethics, University of Plymouth)
Group C: Government policy plans to increase the proportion of patientstaking part in research. What are the implications of this for patients andresearch participants?Chair: Professor Ulf Schmidt (University of Kent)Opening the discussion: Dr Janet Wisely (Director, National Research EthicsService)
8The final plenary session was chaired by Professor Graham Scambler(Professor of Medical Sociology, Research Department of Infection &Population Health, UCL). He outlined the format of the session and brieflyintroduced Professor Stuart Blume who had been invited to give the lastformal presentation of the day. Professor Blume’s presentation The Politics ofPatient Participation brought out some of the wider political considerationsfor those dealing with medical research subjects and provided an excellentframe for beginning to draw conclusions from the day’s proceedings.
C o n c l u s i o n s , R e c ommen d a t i o n s a n d N e x t S t e p s
The variety and richness of discussion at the Workshop made it impossibleto draw together in the final discussion all the insights, observations andproposals for action that had emerged during the course of the day. Withthe advantage of more time, and documentation of the event, the organisershave however highlighted here some of the recurring themes andrecommendations.
Biomedical research involving human subjects has developed rapidly over thelast decades, as have understandings of the role and contribution of patientsand research participants. The latter however remains patchy, and an overallpriority is to increase public, patient and participant influence to addressquestions at both the micro level of the individual participant and individualtrial and the macro level of global trends in healthcare and research,weaknesses in national and international systems of regulation, and pervasiveissues such as trust and equity.
Specific recommendations made include the question of trust and how thisintersects with appropriate levels of governance, and the negative effects ofover­regulation and bureaucracy. Gaps were identified in current regulatoryframeworks regarding social issues, such as complaints procedures, feedbackand the availability of information for those who have taken part. We canovercome mere lip service to the involvement of public and participants inresearch by instating systems that require evidence of good practice in PPIand give due attention to practicalities such as funding. Commercial as wellas publicly funded trials need to be drawn into this culture. Patients, patientgroups and potential participants can make an important contribution toshaping such reforms.
9At the micro level, the participants at the workshop identified a number ofpractical steps that could be taken. Ethics Committees and funding bodiescould encourage the expansion of participant involvement to cover the wholeprocess (engaging with them at the design stage, and through to the end ofthe studies), by making this a condition of approval. The same should applyto feedback from the researchers to participants about the results of thestudies. The training of researchers could usefully include a more carefulconsideration of the roles of their participants, and the range ofcontributions that terms such as 'subject' or 'partner' might imply.
The conclusions and discussion from the Workshop are to be furtherdeveloped in the Research Volunteers Forum which has a dedicated website(www.ucl.ac.uk/researchvolunteersforum), where more detailed information onthe proceedings of the Workshop is to be found, including audio podcasts ofall the presentations. The expectation is that individuals and organisationswill have been motivated by these discussions to take up the themes mostappropriate to their sphere, and create more developed plans of action.
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A BOU T T H E WOR K S HO P
Current research strongly suggests that the quality of the relationshipbetween the researcher and the researched subject is crucial for theachievement of both volunteer satisfaction and successful and reliableresearch outcomes. The organisers of this Workshop believe that suchfindings have policy implications for:
• the design and management of clinical trials and other experimentalbiomedical research using humans
• revisiting the concept of the volunteer that is embedded in researchregulation and ethical codes
• the role of patient advocacy groups
• researcher training
• policy­makers, politicians and executives concerned with strategicpriorities
The Workshop provided an opportunity to discuss such issues with a widerange of organisational and individual stakeholders in the research enterprise(including researchers, patients, patient groups, funders, managers andpolicy­makers). The format of the meeting placed an emphasis on sharingthe expertise and perspectives of all participants. Presentations were keptvery short, with extended provision for break­out groups, debate andnetworking. Together, these stakeholders reviewed the scope for joint andindividual action and collectively suggested ways forward.
We have set up a dedicated website (www.ucl.ac.uk/researchvolunteersforum)where the links forged on the day may be maintained, and discussions andrecommendations further developed. This site also provides access to bothpodcasts and transcripts from the workshop presentations. Please click onthe icons (as below) to link directly to the relevant multimedia material onthe website.
Listen to presentation
Read presentation transcript
12
WOR K S HO P
Brian Balmer / UCL
Stuart Blume / University of Amsterdam/ Innovia Foundation
Sophie Broster­James / Medical Research Council
Victoria Cambridge / Royal Society
Meg Clinch / Cambridge University
Jane Cope / National Cancer Research Institute
Oonagh Corrigan / Peninsula Medical School, Plymouth University
Diana Dunstan / Gt Ormond St Charity Trustee
Leila Eadie / UCL
Sharon Fullerton / Patient­Volunteer
Sophie Gasson / Cancer Patients Research Group
Kate Harvey / Nuffield Council on Bioethics
Jem Hebden / UCL
Mark Jarvis / Patient­Volunteer
Susan Kerrison / UCL/UCLH
Anne Lancely / UCL, Women's Health
Alex Leff / UCL, Institute of Neurology
Karen Lowton / KCL
Jackie Maull / Association of Research Ethics Committees
Stephen Mawdsley / Cambridge University
Hugh Middleton / Nottingham University
Adrienne Morgan / Independent Cancer Patients’ Voice
Carolyn Morris / COMPASS Consumer Liaison Group
Norma Morris / UCL
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Erika Narkiewicz / St Mungo’s
Naomi Pfeffer / UCL
Vivienne Quirke / Oxford Brookes University
Nadia Robb / UCL
Graham Scambler / UCL
Ulf Schmidt / University of Kent
Jill Shawe / UCL, Women's Health
Judith Stephenson / UCL, Women's Health
Fiona Stevenson / UCL
Maryrose Tarpey / INVOLVE
Harriet Teare / Cancer Research UK
Lorena Teran / University of California, Irvine
Shana Vijayan / UCL
Maggie Wilcox / Independent Cancer Patients’ Voice
Catherine Will / University of Sussex
Janet Wisely / The National Research Ethics Service
Louise Wood / Department of Health
Zoe Wood / UCLH
Rosamund Yu / UCLH/UCL
P A R T I C I P A N T S
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10.00 /Professor Malcolm Grant (UCL Provost) Welcome
10.10 /Research Reports
Chair: Professor Hugh Middleton, School of Sociology and Social Policy,Nottingham, and NHS Consultant Psychiatrist
Norma Morris, Jeremy Hebden, Sharon Fullerton and Brian Balmer (UCL)Optical Imaging participant­involvement project: ‘Just bodies’ or partners inresearch?
Alex Leff Consultant Neurologist (UCL) and Mark Jarvis (participating patient)Treating patients using the internet
Lorena Teran (University of California, Irvine)Research participant engagement at University of California, Irvine
10.40 /Questions and discussion
11.00 /Coffee Break
11.30 /The contribution of Patient Groups and PPI
Chair: Dr Louise Wood, Deputy Director, R&D Directorate, DoH
Dr Adrienne Morgan, Maggie Wilcox (Independent Cancer Patients’ Voice)ICPV’s role and policies
Dr Jill Shawe (Margaret Pyke Centre for Sexual and Reproductive Health)The Research and Innovation ForumDr Naomi Pfeffer (UCL)Reflections on ‘CERES’ (Consumers for Ethics in Research)
12.00 /Questions and discussion
12.20 /Governance, Sponsorship and the Participant
Chair: Dr Louise Wood, Deputy Director, R&D Directorate, DoH
Dr Jane Cope , Director, National Cancer Research Institute (NCRI)Dr Susan Kerrison, (UCL/UCLH Joint Unit)Research Governance and PPI ­ the view from a large Trust
12.45 /Questions and discussion
13.00 /Lunch
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14.15 /Breakout Sessions
Group AChair: Carolyn Morris (COMPASS User Involvement Group)
Opening remarks: Maryrose Tarpey (INVOLVE)
Does Patient and Public Involvement (PPI) , as presently practised, affect theexperience or level of involvement of actual ‘research participants?
Group BChair: Dr Brian Balmer (UCL)
Opening remarks: Dr Oonagh Corrigan (Associate Professor in Sociology andEthics, University of Plymouth)
Are the people enrolled in a clinical study best (or most accurately) describedas participants, collaborators or research subjects?
Group CChair: Professor Ulf Schmidt (University of Kent)
Opening remarks: Dr Janet Wisely (Director, National Research EthicsService)
Government policy plans to increase the proportion of patients taking part inresearch. What are the implications of this for patients and researchparticipants?
15.30 /Coffee Break
16.00 /Plenary Session
Chair: Professor Graham Scambler (Professor of Medical Sociology,Research Department of Infection & Population Health, UCL)
Professor Stuart Blume (University of Amsterdam and Innovia Foundation)The Politics of Patient Participation
Rapporteurs from the Break­out GroupsReports from Break­out Groups
17.10 /Questions, discussion and where next
17.30 /Close
A G E N D A
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WOR K S HO P W E L COM E
UCL Provost, Professor Malcolm Grant opened the workshop with a fewwords.
He commented that for UCL, (in common with many institutions) a primarygoal is to ensure that mankind receives the benefits of its research. Thestrong connotations of the terms ‘basic research’ and ‘applied research’ haveperhaps impeded this process. A university is publicly funded to do thingsthat are of public benefit. This includes not only basic discoveries but alsotheir translation into concrete results.
The notion of translation, finding a ‘route out’ of the laboratory into thepopulation, has been key for UCL in discussions with organisations such asCancer Research UK, the Medical Research Council and the Wellcome Trustwho have funded the new medical research centre being developed at StPancras. Partnerships between UCL and hospitals such as Great OrmondStreet, Moorfields, UCL Hospital and the Royal Free are also immenselyimportant because they allow us to ensure that teaching, research andclinical practice are more closely joined together. The success of this can beseen in last year’s project looking at the treatment of strokes in the NorthCentral London area. The incidence of lasting damage has been dramaticallyreduced and we hope to repeat that success with further work on cardiacand cancer treatment.
However, an important aspect of the ‘translational pipeline’ is that workingwith patient groups and human subjects is very different from working withmice! It is only when new discoveries come into contact with humans thatwe can understand their likely impact. This is a difficult and costlyenterprise, in which we have been overtaken by the US and China. Thisworkshop has the potential to make major contributions to ourunderstanding of the use of volunteers and to developing better practices inclinical, translational research.
18
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R E S E A R C H R E PO R T S
The workshop began with presentations by researchers in both biomedicaland social sciences and participating research volunteers. They gave someperspectives from the field about their experiences of working in partnershipin research. The session was chaired by Professor Hugh Middleton, School ofSociology and Social Policy, Nottingham and NHS Consultant Psychiatrist,who introduced the short presentations.
The first presentation was from the organisers, about the study that wasboth the basis of an extended research project, and the origin of theworkshop itself. The presenters were a group made up of a researcher fromthe Science and Technology Studies department, UCL, Dr Morris, withProfessor Jeremy Hebden who is developing new optical imaging techniquesfor the breast, and one of the research participants who had helped with thedevelopment of this new technology, Ms Fullerton. Together they gave anoverview of what they had discovered about the potential for participants’roles in the research process, and the ways in which good workingrelationships were developed. Dr Leff and Mr Jarvis, gave a presentation oftheir innovative work taking research (and treatment) out of the lab, andonto the Internet, and their observations of changing roles. Finally, Dr Terangave an overview of some of the aims and new practices being developed atthe Institute for Clinical and Translational Science, University of CaliforniaIrvine to promote a more reciprocal relationship between researchers andcommunities.
The discussion that followed raised questions about how to develop andmaintain successful relationships between researchers and participants,particularly over longer­term projects, and how both communication andfunding practices might affect these. There was also some discussion aboutthe accreditation and ownership of research results where participants hadbecome highly engaged in the research process.
20
Professor Hebden opened the presentation. He described the work of hisresearch team who are developing a new optical imaging system to buildimages of the breast using harmless pulses of light. A first prototype wasdeveloped which required the patient to lean against a frame (Image 1). Thetesting of this prototype was done in collaboration with Norma Morris, whointerviewed each of the volunteers after each study. These interviewsgenerated interesting feedback that allowed the physicists and engineers tomodify the system to be more patient­friendly. These modifications increasedcooperation from the volunteers, and improve the quality of data. A secondprototype was developed with a different system (Image 2). Further studiesand interviews have led to continued refinement of the equipment.
Dr Morris described the key findings from her interviews with the participantsand participant­observation of the optical imaging research. There were a fewparticipants who described themselves as happy with the notion of being ‘justbodies’ as opposed to active participants, but at the same time feltambivalent or hostile to the idea of being a ‘guinea­pig’. More commonlyparticipants sought an equal and active role, and felt themselves empoweredby ‘giving’ to medical research in this situation where they could expect nodirect benefit. Another volunteer described herself as a ‘pioneer not victim,’i.e. as active, not passive, a reminder of the effort required for achieving andsustaining productive relationships in research.
Sharon Fullerton spoke as a participant in this study. She had come to beinvolved after successfully recovering from bilateral breast cancer. Herconsultant surgeon had invited her to participate in the study in 2007.Sharon had agreed both from gratitude for the quality of care she hadreceived but also due to her independent involvement with cancer charities.
She noted several ways in which she had been made to feel comfortableand valued as a volunteer. Prior to the study she had received detailedinformation beforehand about the tests. On the day itself she was met atthe lobby, guided through the hospital and introduced to each person whowas present. The closing interview by Norma Morris was a ‘really nice way of
‘ J U S T BOD I E S ? ’
D r N o r m a M o r r i s , P r o f e s s o r J e r em yH e b d e n ­ memb e r s o f t h e r e s e a r c ht e am a n d S h a r o n F u l l e r t o n ­r e s e a r c h p a r t i c i p a n t
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finishing the morning’. Sharon was also pleased to have received updatesabout the study by email, these leave her continuing to feel her participationwas worthwhile.
The speakers left the audience with two key questions to be consideredduring the workshop:
What is it like to be a participant, a research volunteer in medical research?What scope is there to be more than a ‘lab rat’­ more than just a body?
Image 1: UCL optical mammographysystem, first prototype Image 2: UCL optical mammographysystem, second prototype
22
Dr Alex Leff has been developing a behavioural treatment for a conditioncaused by a stroke that affects people’s vision, and in particular theirreading. The treatment, Read­Right, is structured reading practice using textthat is rolling across a screen. This exercise produces an increased speed ofbetween 30­50% when the patient returns to static text.
The treatment was proven to be effective in a controlled clinical trial wherethe therapy materials (moving text at different speeds) was recorded ontovideotapes and sent to patients' homes. However, after the trial finished thequestion remained of how to get it ‘out there’. With funding from the StrokeAssociation and UCL Multimedia he decided to make the therapy freelyavailable on a website.
This led to a new set of challenges. Initially these were related to developinga useful and attractive interface, but then the team decided to ask anadditional, scientific question­ does putting the therapy on the website haveas good an effect as when it is done in a clinical trial? This made good webdesign all the more important. Finally the problem of distribution arose­ howcan you bring this therapy to the attention of patients? On these issuespatient input proved to be crucial, and Dr Leff introduced Mark Jarvis, apatient who had collaborated with the research team on these questions.
Mark Jarvis explained how he had met Dr Leff. He was suffering from thecondition of hemianopia­ a loss of the field of vision in his right eye.Although he later learned that this only prevents ‘pre­reading’ (as those withstereovision are able to do), he initially thought he had lost the ability toread properly.
His role in helping to develop Read­Right. was to work with the design toimprove his ability, as a patient, to use the website­ for example, initially thecontrols were placed on the right hand side of the screen, where it wasdifficult for him to use them. They also changed colours and fonts to adaptit for people with the condition, and introduced a variety of different kindsof reading matter, books, articles, tabloid newspapers and so on. He foundit really beneficial that his views, as someone with the condition, were
T R E A T I N G PA T I E N T S US I N G TH EI N T E R N E T
D r A l e x L e f f , c o n s u l t a n tn e u r o l o g i s t , UC L I n s t i t u t e o fN e u r o l o g y a n d M a r k J a r v i s
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valued by the researchers, and put to use, and going out direct to thepublic and other patients by the website. His participation had alsocontributed to a greater sense of confidence. This partly came fromunderstanding his condition better, that it was his visual impairment thatslowed his reading, and there was nothing wrong with the 'reading' part ofhis brain. It had also however allowed him to go back to givingpresentations. Public­speaking had been very difficult whilst reading had madehim feel anxious.
Mark had also played a significant role in publicity and generatingawareness. One key moment for the website was an article in the Mail onSunday. This increased the number of participants, and Mark found himselfinundated with emails and phone calls asking for more information aboutRead­Right. As a sufferer, he could appreciate that the loss of a skill thatpeople had acquired from an early age was very frustrating for most people.Being able to assist people using the knowledge he had gained fromparticipating in the research was a very fulfilling experience.
Screen shot from the demo version of Read Right / www.readright.ucl.ac.uk
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R E S E A RCH PA R T I C I P A N TE NGAG EM EN T A T UN I V E R S I T Y O FCA L I F O RN I A , I R V I N E
D r L o r e n a T e r a n , U n i v e r s i t y o fC a l i f o r n i a , I r v i n e
Dr Teran gave an overview of the work underway at the University ofCalifornia, Irvine in the Institute for Clinical and Translational Science. Thedepartment have recently set up a Community Engagement Unit (CEU). Thisunit creates a space for collaboration between students, scholars,researchers and community organisations on projects that have beengenerated by the community.
This unit is developing research practice based on the principles ofCommunity­based Participatory Research (CBPR). These are founded onshared decision­making and shared ownership of research findings andknowledge benefits between all the partners involved. This style of working isnew to UC Irvine, however, useful results have been gained from those fewprojects where the community has been involved, particularly in behaviouralresearch.
Applying CBPR requires inventing new ways of working but generates benefits.In usual practice, research groups have to work to identify a patientpopulation. As an example, there are many studies on obesity prevention,and a large Latino population in southern California. No one on the researchteams however speaks Spanish or has a Latin background; the skills thatwould allow interaction with participants on their own terms. Involving thecommunity and building the project together prevents this kind of problem.
This has an impact on research agendas. Typically these are based onclinical data, investigators’ research interests or funding opportunities. Havingmore diverse research teams helps to identify and define clinical issues fromthe community’s point of view. The community representatives are not onlyadvisors, but also serve on decision­making bodies.
It also affects recruiting, which would traditionally be done through websites,local doctors or advertisements. The CEU are working to persuade researchorganisations to educate local community groups and hire individuals withinthe community as health outreach workers. These can in turn recruitvolunteers.
They have also set up the Community Action Planning Group. The role of
25
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this group is to act as an intermediary between researchers and community­based organisations. This group is involved in providing services such asblood pressure monitoring, or glucose testing and simultaneouslydisseminating findings beyond peer­review journals. The volunteers feel moreinvolved and the community partners help with advocacy for policy change.
Direct benefits to the CBPR approach are that you have a better­balancedtrial with more diverse patient populations, particularly those currently under­represented. You also increase patient trust, which has not always beensufficiently cared for in the past.
Finally, this communication between partners can be difficult, there arechallenges to bridging the different perspectives. It can take many meetingsand a lot of communication to get people on a level playing field. The CEUhave two particular initiatives to address this. Firstly, the Campus CommunityResearch Incubator Awards provide funding for the early stages of discussionbetween researchers and community organisations. Secondly they are workingto motivate community groups and volunteers through award systems andstipends.
In conclusion, the work of the CEU using CBPR has produced interestingresults and feedback from previously hard to reach populations.
The Community Engagement Unit at work­they visit community health fairs and provideparticipants with their BMI and bloodpressure for free
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R e s e a r c h R e p o r t s : Qu e s t i o n s a n dD i s c u s s i o n
S u s t a i n i n g p a r t i c i p a t i o n
The first question raised was about the challenge of sustaining an ‘individual’relationship with participants in studies that extended over long period oftime – six or seven years for example.
• One suggestion, from a patient and research participant, was that thekey lay in maintaining regular contact through sending outinformation or updates to sustain interest and the sense ofinvolvement
• Another suggestion was that participants might be invited to commenton how the trial processes might be improved in the light of theircontinuing experience. Although study protocols were not normallyopen to change, there was a case for considering more flexibleapproaches to design that permitted procedures to be modified inthe light of participant feedback.
• A patient/participant also cited the Million Women Survey andBiobank as examples of how regular contact and information couldsuccessfully sustain participant commitment over a long period.
L e v e l s o f p a t i e n t p a r t i c i p a t i o n
Some divisions were observed at the strategic management level of largenational studies with regard to volunteer research participant involvement(where provision of information was generally thought to be well­managed)
• Biobank, for example, had shown itself not to be open to anapproach from a patient group to meet with managers to learn moreabout the governance of the study. This contrasted with, for example,a breast cancer­specific database launched by one of the cancercharities, where there were patients on the management board andon key committees, commenting on all aspects of the work
• Some of this difference might be accounted for by differences in thenature of the database and the participant population, i.e. the one anational DNA bank based largely on healthy volunteers, and the othera disease­specific tissue bank, necessarily patient­based.
I m p r o v i n g f e e d b a c k t o p a r t i c i p a n t s
Examples were given of poor practice (in major trials centres) regardingfeedback of information on study progress to participants. This elicitedsuggestions for ways of improving this situation, drawing on practices alreadyput in place by some individuals and institutions:
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• Run courses on Participatory Research for both researchers andcommunity or patient­based organisations (and make sure bothcome!)
• Use the Internet for both individual (eg test results) and study groupfeedback. Attention was needed to confidentiality and copyright (egre scientific publications) issues, but these were surmountableproblems
• Where the individual participant’s voice is apparently not listened to,they could bring to bear added leverage by speaking as a memberof a patient group
P r a c t i c a l i t i e s o f i n v o l v i n g f a c u l t y a n dc ommun i t y
In response to a question regarding the involvement of faculty (ieresearchers) on issues around active participation, it was noted that theproportion of those committed to this approach was still very small. Likewiseit was easier to deal with organised groups rather than with unorganisedpatients. Nevertheless efforts were being made to widen the coverage,including the following:
• Holding workshops and courses
• At University of California, Irvine, a system of Incubator Awards –small cash grants available for work contributing to setting uppartnerships
• Making training available for patients and community members to helpthem hold their own, play active roles within advisory or managementcommittees, and communicate their valuable experience and views
• Ensuring patients as research participants felt confident enough tospeak up with their comments or suggestions on the design andconduct of the research
Own e r s h i p o f r e s e a r c h r e s u l t s
The final topic raised in this discussion session was on the ownership of theresults of research. How far might researchers (or their sponsors) be willingto share the fruits of research with the research participants? This provokeda range of comments and suggestions, including:
• Sharing information about results had already been identified asimportant to participants, should Ethics Committees therefore beencouraged to insist on this as a formal requirement?
• Extending the practice of co­authorship of publications withcommunity/patient partners
28
• Sharing financial benefits (where there were any) was noted tobe problematic in many ways, not least because of the ethical issuesit raises. But the question remained open: should we find some wayof “being like John Lewis” (ie a partnership that embraced allmembers of the enterprise, who all had some share in the profits)?
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T H E CON T R I B U T I O N O F P A T I E N TG ROU P S & P P I
This session was chaired by Dr Louise Wood, Deputy Director, R&DDirectorate, at the Department of Health. The session aimed to examine howorganised groups, whether patient­ or researcher­led, may contribute to theresearch participant’s experience. Dr Morgan, and Mrs Wilcox gave apresentation of the campaigning activities of the ICPV­ Independent CancerPatients’ Voice group, which have included organising study days to promoteresearcher­patient/participant dialogue, and efforts to increase patient voiceat structural levels in research organisations. Dr Shawe, supported by Forummember Erika Narkiewicz, gave an overview of the creation of the newResearch and Innovation Forum that exists to give the local communities agreater role in organising and steering the research of the Margaret PykeCentre for Sexual and Reproductive Health. Finally Dr Pfeffer gave anoverview of her work with CERES (Consumers for Ethics in Research) acampaign group that had led the way in promoting participant empowerment,and good practice amongst researchers.
The session ended with debate on a number of issues including the diversityof the patient/research volunteer community, and consideration of how thatcould be best represented. There was also discussion of structuresembedded within research procedures that were inhibiting patient involvement,these included power relationships, but also rules of confidentiality whichmay leave participants unable to seek support from peer groups.
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TH E RO L E AND PO L I C I E S O F TH EI N D E P E ND EN T CANC E R P A T I E N T S ’VO I C E ( I C P V )
D r A d r i e n n e M o r g a n a n d M a g g i eW i l c o x ( I C P V )
Dr Morgan began with a quotation from one of the founders of ICPV.“Research is improved by patients being partners with physicians andhealthcare professionals, rather than passive recipients of healthcare.” Thisoutlines their philosophy as a patient advocate group led by patients,independent of established cancer charities, that has been working since2009. Their aim is to bring the voices of the patient, carers and relativesinto the cancer research community, and they have developed a number ofstrategies to do this. Dr Morgan outlined some of these; study days,members involved in clinical research, and an active Google group as aforum for discussion.
ICPV has been involved with a number of clinical trials that cover a range ofissues. In addition they have also been involved with the new Breast CancerCampaign tissue bank initiative. This has resulted in clinicians andpathologists having greater awareness of patients’ willingness to consent todonate material. It has also led towards a change in attitude to tissuebanking, the banks as custodians rather than owners of the material.
They have also organised four study days by approaching centres ofexcellence and researchers directly. Basic travel and accommodation costshave generally been supported by donations from the drug industry butotherwise the group has no source of funding. Discussions at the StudyDays have tackled consent, pathology and tissue­banking, the breast cancerscreening debate, and also the design of clinical trials. The most recentevent took place at the Houses of Parliament where the ICPV hosted a‘Dragon’s Den’ style forum for researchers designing new clinical trials wherethere was also a discussion about the 23­hour pathway for breast surgery.
ICPV have also produced a variety of documentation from discussion papersto leaflets promoting the tissue bank initiative and a patient­to­patient leafletexplaining the benefits of participating in clinical trials.
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Photograph from the National Cancer Intelligence Network(NCIN) conferencePhoto credit: Adrienne Morgan
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R E S E A RCH I N NOVAT I ON FORUM
D r J i l l S h a w e , Ma r g a r e t P y k e C e n t r ef o r S e x u a l a n d R e p r o d u c t i v e H e a l t ha n d E r i k a N a r k i e w i c z , MP C F o r umm em b e r a n d R e g i o n a l H e a l t hC o o r d i n a t o r , S t M u n g o ’ s N E L o n d o n
Dr Jill Shawe is both researcher at UCL and clinician at the Margaret PykeCentre. This centre is part of the Central Northwest London Trust andprovides sexual health services for the whole area. When she joined thecentre it became obvious that more patient involvement was necessary, andthis eventually resulted in a Research Innovation Forum which was createdwith Dr Zara Haider, a colleague who was looking at setting up a communitygynaecology service.
So why did they do this? Patient involvement was important for a number ofreasons. Firstly that the patients themselves have great ideas for research,and it was important to find a channel for them. The centre was at the endof a trial for a contraceptive pill and the patients were actively seekingfurther ways to be involved. The Forum was seen as a useful place to thinkabout the pathways that patients would use to access the proposedcommunity gynaecology service and finally the centre wanted advice on theirwebsite from the users.
The Forum applied for funding from the UCL Public Engagement unit andthat started things off. They used the Camden Community InformationService (CINDEX), contacted every community group and invited them to bestakeholders in the project. Two important partners emerged, the FitzroviaWomen’s Centre that works largely with Asian women, and St Mungo’s.
Erika Narkiewicz spoke on behalf of St Mungo’s which is a large organisationfor the homeless and runs several big hostels in the Camden area. She washappy to have been invited to join the forum as she usually has toapproach the healthcare providers herself.
From September the patient forum will be chaired by one of the patients. Animportant problem to solve is how to get beyond email as a means ofcommunication, whether Facebook or media completely outside of theinternet, posters, flyers and so on. The patient pool for the organisationsincludes homeless people, asylum seekers, people from ethnic minorities andyouth groups, and they want to widen participation. They are keen to gather
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more information about what research is needed and how to improveservices. A final outreach project is participation at a community fair, settingup a stall that is planned as an annual activity.
The latest news is that a forum­member has been involved with a grant­application process for funding using community pharmacists and thereforeengaged in the project right from the start. A positive step for the Forum.
Flyer from the recruitment stage of the Margaret PykeCentre Research Innovation Forum
34
R E F L E C T I ON S ON ‘ C E R E S ’(CONSUME R S FOR E TH I C S I NR E S E A RCH )
P r o f e s s o r N a om i P f e f f e r , UC L
Prof. Pfeffer described the work of CERES and some of the lessons learntfrom participating in the organisation. The organisation was initiallyestablished in 1988 as the Standing Committee of User Organisations forPregnancy, Childbirth and New Developments in Reproductive Technology..From this CERES emerged but was campaigning around the patient role inmedical research more broadly.
When the group was established, they undertook some research into thestructure of medical charities. At this time these were most often structuredvery similarly; a scientific committee composed of eminent practitioners orresearchers, and a lay group who were only involved as fundraisers. CERESaimed to act quite differently and was interested in raising consciousnessand getting patients involved with drawing attention to the issues that wereof immediate concern to them.
The group earned money through small grants and from the sale ofpublications. One of these was a booklet Spreading the Word on Research,funded by the North­East Thames Regional Health Authority advisinginvestigators on how to produce comprehensive, comprehensible patientinformation. This was sold and used extremely widely. A second importantpublication was the Medical Research and You leaflet, ratified by the PlainEnglish Campaign and also sold and distributed very widely. Other similarprojects also produced publications, often providing information in variouslanguages and also on tape.
Other activities included public meetings, as for example one held onresearch into Sickle Cell and Thalassaemia. These meetings brought upspecific issues, such as the very poor quality of patient information materialin clinical trials, and also the general interest from patients in more socially­oriented research into their conditions, investigating for example the factorsthat might provoke crises.
The organisation closed in 2006. There were several issues at that time. Onewas that Medical Research and You was being used inappropriately by a
35
CO
NT
RIB
UT
ION
OF
PA
TIE
NT
GR
OU
PS
&
PP
I
company that was recruiting for healthy volunteers (and involved in anotorious incident in 2006 where several healthy volunteers required intensivecare). Another was that patients were looking for more specific advice andsupport than CERES was able to give. Finally there had been a move tocreate an independent advice and information service for research subjectsas a statutory requirement under the EU Clinical Trial Directive, although thiswas, in the end, dropped from the legislation.
The experience of working with CERES brought several lessons, which DrPfeffer invited participants in the Workshop to keep in mind during furtherdiscussions:
There is no single research subject’s view on medical research.
There is no agreement on why researchers and their sponsorsshould take note of research subjects. Is it for:
better science?better ethics?easier recruitment of research subjects?the development of more appropriate health care?the creation of new markets?confirmingormonitoring investigators’compliancewithregulations?
Structural inequalities in power must be recognised.
The landscape of clinical research changes, so there needs tobe constant reassessment of what it means to have a patientvoice.
Spreading the Word onResearch, CERES publication,1994
Medical Research And You,CERES publication, 1994
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T h e C o n t r i b u t i o n o f P a t i e n t G r o u p sa n d P P I : Qu e s t i o n s a n d D i s c u s s i o n
D i v e r s i t y o f t h e p a t i e n t c ommun i t y
The first topic raised was how far the patient body or community – oftenreferred to in the morning’s talks – was a coherent one. Were all voicesequal in that body? And more specifically in terms of the history of patientgroups did something special happen when doctors and medical scientistsstarted to talk about their experience as patients, and could thus speak witha dual voice? Were there issues of structural inequality in the ‘patient voice’,which needed to be addressed? Among the points raised in the ensuingdiscussion were the following:
• There was great diversity and members of patient groups should bethought of as advocates – rather than representatives, as they couldnot and did not claim to be ‘representative’ of patients as a whole
• Scientists had to learn to be patients, as patients had to learn to becomfortable with science, and advocates had to earn their place atthe table and earn respect by making valuable and relevantcontributions
• Things had moved on since the pioneering early days. Both the AIDscommunity and the Women’s Health movement had been importantinfluences in winning acceptance for an active patient role, thoughinequalities of power of course remained at the level of both theindividual and institutional influence.
R o l e a n d f u n c t i o n s o f p a t i e n t g r o u p s
• Patient groups had a role in proactively seeking out patients withlatent capacity for the advocate role and in sustaining momentumand energising their members through the enthusiasm andorganisational enterprise of the collective
• Ensuring a range of perspectives through bringing in carers, youngpeople, children and those patients totally dependent on care. (Thework of NIHR’s Medicines for Children Clinical Research Network andNRES in producing guidance on the involvement of children inresearch decisions was welcomed in this context.)
• Maintaining the morale and commitment of partnership groups throughvicissitudes in funding (a role or responsibility shared withresearchers)
• Drawing attention to the practical issues associated with the quest fordiversity (e.g. lack of provision for the cost of carers’ time)
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I s t h e r e a s p a c e f o r t h e v o i c e o f r e s e a r c hp a r t i c i p a n t s ?
• Patient groups are held back from developing direct channels ofcommunication with research participants because current rules ofconfidentiality deny them access. These rules need to be challengedso that more effective liaisons between patients on ManagementGroups and participants can be established
• Consideration could be given to inserting a clause into standardresearch forms regarding consent to further contacts. This mightalleviate this situation
• Researchers and health professionals may still need reminding thatthey do not always know best what research participants andpatients generally want and need
• It remains a concern that the total number of researchers activelyinvolving patients – or participants – in the research is a very smallproportion of the whole (a claim substantiated by figures collected by‘INVOLVE’ up to 2010)
38
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GO V E R NM E N T , S PON SO R S H I P &T H E P A R T I C I P A N T
This panel, also chaired by Dr Wood, explored the role of the majorinstitutional structures around research governance, regulation andsponsorship in shaping the research participant’s experience.
The first presentation, given by Dr Jane Cope of the National CancerResearch Institute, gave an overview of how attitudes towards patientparticipation had changed during the course of her career and how differentpractices had evolved, particularly in relationship to governance. She drewattention to issues around assessing the level of regulation most beneficialto patients. The second presentation by Dr Susan Kerrison of the UCL/UCLHJoint Unit framed PPI within the context of the vast number and extremes ofscale of studies that take place in this organisation each year. Shehighlighted the diversity of roles that research participants play in these.
The ensuing discussion debated the role of PPI in various kinds of research,and research environments, what it might contribute, how it should beevaluated and its impact assessed in different situations. Specific areasidentified for action included the sharing of information, lack of regulatoryattention to social and structural contexts affecting participation, and PPI incommercial trials.
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P A T I E N T AND PUB L I CI N VO L V EM EN T A T TH E NA T I ONA LCANC E R R E S E A RCH I N S T I T U T E
D r J a n e C o p e , D i r e c t o r , N a t i o n a lC a n c e r R e s e a r c h I n s t i t u t e
Dr Cope presented some personal reflections on nearly 30 years' experienceof research involving patients. This began in her work setting up AIDSresearch in the UK in 1980s. The patients here were mostly young, gay menwho were very vocal about their involvement. This followed on from theculture of AIDS research in the US where patients had actually re­organiseda trial because they found a placebo­controlled method to be unethicalgiven the prognosis of the condition. At that time cancer research in Britainhad very little patient involvement, to the extent that patients in trials didnot necessarily know the nature of their condition, or that they wereparticipating in a trial. This changed hugely over the following 30 years, andcancer research trials are now at the forefront of patient involvement, achange that in itself makes an interesting subject for study.
An example of recent good practice would be a trial for treatment ofprostate cancer (ProtecT). The research group wanted to compare threedifferent treatments, surgery, radiotherapy and active monitoring, but didn’tknow whether patients would be willing to be randomised into one of these.One of the principal investigators is a social scientist and ran focus groupsthat dealt with the delivery of information, consent processes, and the trialhas proved very successful.
The NCRI use the term consumer. This is controversial, however they havefound that patients, users, survivors, service­users, all these terms are lovedand hated by different people. This emphasises that there is no singleconsumer viewpoint and equally no single formula for doing involvementcorrectly.
This situation poses problems when it comes to research governance.Advocating governance is obviously done with a concern for patient safety,but does more governance lead to more benefit to patients?
It has been assessed that the EU Clinical Trials Directive has doubled thecost of academically­led trials which probably means that the number hasbeen halved. Is that in patients’ best interests?
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Another issue that has emerged is that certain patients are beginning tothink of themselves as having a ‘right’ to be involved in trials. Evidencesuggests that patients on trials, or in hospitals that have a research culturehave better outcomes. Therefore more people are requesting to be involved.The NCRI had a letter from a breast cancer patient complaining that hertissue had been thrown away, but she was unaware of the paperworkrequired to regulate access if it was to be preserved.
There is a line to be drawn as to what levels of regulation and governanceare most beneficial to patients.
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Each year around 500 research studies on patients or their data areregistered at UCL­UCLH. Rather than talking about the diversity of thepatients, Dr Kerrison focused on the diversity in studies and implications ofthis for involving patients. She looked at three factors, funding arrangements,study objectives and study size.
Funding for medical research in the UK comes from three main sources,from medical research charities, through public funding, or throughcommercial research (or sometimes a combination of all these).
Medical research charities have the highest level of public involvement. AsMichel Callon showed in his studies of patients with muscular dystrophy, thelong term engagement of patients in research into their condition, can leadto a co­production of research, with increased funding and development ofnew treatments. Patient engagement is therefore crucial for those interestedin investigating rare conditions.
Public funding is another source of financing. Public involvement in decision­making is now in vogue for all parts of the NHS including research. Anapplication for public funding now requires the applicants to state how theywill involve the public in the funded research. This has promoted theinvolvement of patients.
Finally there is commercial research. Making patient involvement a reality incommercially sponsored studies seems to be more of a challenge. Figuresfrom the MHRA obtained under the Freedom of Information Act show thatcommercial sponsors run about four times as many trials each year asacademic sponsors. Companies undertaking trials in UK may be globalplayers –based outside the UK. Are UK polices for patient involvement likelyto be influential on their activities? A trial may be conducted in manydifferent countries simultaneously. How does meaningful public involvementwork in this situation?
R E S E A RCH GOV E RNANC E ANDP P I ­ TH E V I EW F ROM A LA RG ET RUS T
D r S u s a n K e r r i s o n , H e a d o f R i s ka n d R e g u l a t i o n , J o i n t U C L /UC L Ha n d R o y a l F r e e R e s e a r c h O f f i c e
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Research methods may also set the parameters for patient involvement. Atrial for a promising therapy where there is no other treatment will offer avery different patient experience from one that is non­therapeutic. Somestudies require multiple examinations and hospital visits – others may posefew demands other then signing a consent form. Some research subjectsmay be single players e.g. having gall bladder removed or repeat players iethose with long term conditions. All these issues may have bearing oncapacities for and type of patient involvement.
Finally, there is the question of the size of the study, this may range fromten subjects, to screening studies that involve hundreds of thousands ofpeople. Addressing patient involvement in these two situations offers verydifferent challenges, conceptual, financial and organisational. If these studiesare also taking place globally in many different centres then that addsanother layer of complexity. Patient involvement may only be possible withcertain types of studies, under certain circumstances. Looking at the diversityof studies raises complex conceptual issues about how patient involvementmight work with different types of studies.
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G o v e r nm e n t , S p o n s o r s h i p a n d t h eP a r t i c i p a n t : Qu e s t i o n s a n dD i s c u s s i o n
I m p a c t o f p a t i e n t i n v o l v em e n t a n d r e l a t e dp r o g r amme s
Initial discussion turned around the impact of the creation of the NationalInstitute for Health Research (NIHR) on research design, funding allocation,and the development of the Patient Benefit programme. Among the pointsmade were:
• While some measurable progress had been made in establishing PPIin clinical environments, it was hard to see its effects in laboratory­based research which commands a very high proportion of medicalresearch funds
• Robust measures of evaluating PPI content were needed. This wouldbe helped by structuring grant application forms so that theyrequired strategies for public involvement (separately from strategiesfor engagement, which is not at all the same thing)
R e g u l a t o r y m a t t e r s
A second theme concerned the regulatory framework for clinical trials,especially commercial trials. Issues raised included:
• Attention to social issues was largely absent from current regulatoryframeworks. Areas to address might be the sharing information withparticipants through regular feedback, availability of treatments post­trial, the artificiality of trial conditions and assumptions aboutparticipants’ roles
• When Patient Groups do get a seat at the table for regulatorydecisions they could best serve the community by attending to thefundamental issues of trial structuring and social responsibility, ratherthan accepting the framework uncritically or taking it as a given. Anexample of the latter was given in discussion of a European Uniondirective
• While the important role of commercially funded trials was fullyacknowledged, it was equally important to pay attention to theirdeficiencies in matters of public involvement and to variable scientificstandards. This latter topic in particular needed to move up thepublic agenda
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R e t u r n i n g t o q u e s t i o n s o f i m p a c t
Returning to the theme of the slow spread of PPI, the debate explored issuesaround the role and contribution of ‘involved’ patients and public, and howfunding policies exerted influence.
• It was noted that doubts were sometimes raised as to thecontribution that patients/publics could make on design and conductof more abstruse and technically demanding (typically laboratory­based) research studies. The counter­argument however was thattechnical competence – or the advantages of a health professional orscientific background – should not be over­valued, since the patientadvocate role was primarily to bring to bear a ‘public’ perspective onthe research and to speak to social and political issues, whichrequired other kinds of competencies
• While it was commonly believed that funding was a driving force inpromoting PPI, might it not rather be a force for promoting lipservice to PPI? To address this, funding policies should beaccompanied by policies to raise the status of PPI as an activity(‘INVOLVE’ was cited as running schemes and awards to this end).However peer review remains dominant in funding decisions and it isquestionable whether the quality of PPI carries much or any weight inthat process
• A separate aspect of funding was the scale of provision for PPIactivities within a grant proposal. This constituted a minute proportionof total funding and was usually inadequate for the purpose. Forexample, (and as referred to earlier) consumers have to bear theirown costs for attending meetings (despite having no institutionalresources to draw on). This discriminates against the less well­off andthose whose health care needs add to costs of travel
• A way forward for the furtherance of genuine PPI might be throughbuilding a requirement for well­planned, good quality PPI intoregulatory and ethical frameworks
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R E F L E C T I O N S & E X P LO R A T I O N
The afternoon session of the Workshop followed a less traditional formatthan the morning’s proceedings. It was designed to elicit the maximumcontribution from all the participants, and consisted of three main sections,each aiming in different ways to promote reflection and deeper explorationof the themes emerging from the morning’s presentations and discussions.
These three sections comprised:
1. Discussion in Break­out Groups
2. Afternoon Plenary address by Professor Stuart Blume on the socialand political context of clinical trials
3 Reports from the Break­out Groups and concluding plenarydiscussion session
Both the plenary session and the Break­out Group reports raised issues thattranscended the frame of the individual clinical study. They stressed theimportance of understanding the meaning of medical research for potentialvolunteers and the range of roles that participants could play. Both exploredthe delicate balance between trust and regulatory safeguards, andweaknesses in current governance systems which concentrate too much onthe early stages of studies (initial patient information and consent) andlacked systematic attention to trial management and social issues of concernto participants. In the global context as well as closer to home, the localpolitical economy of health shaped the choices available to potentialvolunteers, and could result in blurring of research and care. The finaldiscussion included recommendations for reviewing, with patient input, thekind of regulation needed; for evolution of Ethics Committees practices andphilosophy; and for recognising through regulatory systems thatpatient/participants needs went beyond ‘protection’, embracing issues such asinformation, access and appropriate research design.
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TH E PO L I T I C S O F P A T I E N TP A R T I C I P A T I ONP r o f e s s o r S t u a r t B l u m e ,U n i v e r s i t y o f Am s t e r d am a n dI n n o v i a F o u n d a t i o n
Professor Blume opened by saying that he had been asked to talk about‘the big picture’. For this he would draw on his experience over many yearsof looking at questions around new health technologies. What problems orquestions did they solve, what did they not solve, or create? His picturewould not be particularly a UK one since he lived and worked outside theUK.
One of the issues raised by discussions of the role of volunteers andmedical researchers was that of recruitment, which had formed the subjectof very large numbers of academic papers. Many of these centred onrecruitment strategies (recruitment now being a very professionalised, andcommercialised, activity) and in methods and content differed sharply from asmaller number of studies where researchers went out and talked to peopleand enquired about why they participated or did not participate in research.Findings from the latter kind of study underlined known deterrents toparticipation, such as randomisation, or threw up interesting observations likethe value placed by African­American men (but not women) on havinginformation about who paid for a study. A Danish study had demonstratedthe struggle between the wish to add to the common good throughparticipation and the (more compelling) need to assure their personal benefitfrom treatment. In the case of healthy volunteers the determining factor – asshown by a meta­analysis of 13 studies in different countries – was thefinancial incentive, with the single exception of a study in Malawi where theprincipal reason for enrolling was access to health care. This point would bereturned to.
Referring to his title ‘The politics of patient participation’ Professor Blumesuggested that to consider in what sense all this is political we had to standback and think about the rules and conventions governing how research isconducted and the sources of people’s expectations and anxieties. Trust wascrucial, and the kind of thing that could undermine trust was (to use anexample from the Danish study) doubts about the physicians’ or researchers’ability to withstand the influence of the pharmaceutical industry. This couldlead to political demands for higher degrees of regulation of trials. Another
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study found widespread distrust – a sort of communal distrust, historicallybased – of the medical profession among African­Americans. The commongeneral point here is that participants’ reasons extend beyond specific detailsof the trials, to concern trust in the people doing the study.
Additionally, there has been overt politicisation of clinical trials, throughpatient activism such as shown by the HIV/AIDS community, which led tochanges in the regulatory framework for trials in the US. Again in the USthere was a change of policy around the issue of who – what sectors of thepopulation should be invited to participate in clinical trials, leading to greaterinclusion of eg ethnic minorities and women. The effects of this arecontroversial, and may have far­reaching implications for popularunderstanding of research and health care, for questions of access to healthcare and the blurring of boundaries between research and care, especiallywhere resources for care are being cut. This recalls the example of thepopulation in Malawi, and the finding in other African countries that peopleenrol, or enrol their children, in trials as a means of accessing health care.
In summary: to appreciate the inherently political nature of medical research,we have to understand its meaning for potential volunteers, their assessmentof the likelihood of its benefiting themselves, their children or theircommunity and the ways in which the local political economy of healthshapes the choices available to them.
Qu e s t i o n s a n d D i s c u s s i o n
One of the questions raised in the discussion following the talk was how farcultural differences and religious issues might affect participation and whetherthis had been much studied or considered in patient groups – a matter thathad come up for discussion in one of the afternoon’s Break­out groups(Group C). While it was agreed that these were likely to be important, it wasfelt that the subject was under­represented in the literature. Studies inpopulation genetics had led to discussion of the significance of geneticdifference for people’s cultural perceptions of identity, but the cultural contextitself was highly relevant to the implications of research, as Professor Blume’swork on the issues around cochlear transplants where there was a strongdeaf community had shown.
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R e p o r t s f r o m B r e a k ­ o u t G r o u p s
A : Do e s P a t i e n t a n d P u b l i c I n v o l v em e n t ( P P I ) ,a s p r e s e n t l y p r a c t i s e d , a f f e c t t h e e x p e r i e n c eo r l e v e l o f i n v o l v em e n t o f a c t u a l ‘ r e s e a r c hp a r t i c i p a n t s ’ ?
Chair: Carolyn Morris (COMPASS User Involvement Group)Introducing the discussion: MaryRose Tarpey (INVOLVE)
This group’s discussion embraced two main themes. Firstly, what was the roleof PPI in making the experience of being a participant ‘more beneficial’?Secondly how far PPI had developed a role and a voice in influencingresearch at the strategic level? At the study level there was no clear patterndiscerned in interactions between PPI activities and participants. There was afrequent lack of clarity regarding roles and expectations – whether publics orpatients (the two ‘Ps’ of PPI), participants or researchers. However these wereall matters that needed further thought.
The governance framework for research could be unhelpful. The system isfront­loaded with more intense scrutiny being given to preliminary and earlystages of a study. PPI activities had also fallen into this pattern. Though itwas important that PPI influence should be brought to bear on individualstudies at the earliest possible stage in the project, that influence needed tobe sustained through the rest of the experience. More focus is needed on,for example, improving systems to deal with complaints and tackling patients’fears about voicing problems. There is also room for positive action here –through simple mechanisms that acknowledge the participants' contribution,thank them and feed back information on results. Payments to participantswere also discussed here, but this notion elicited mixed views, with somevoicing the opinion that they could get in the way.
The bureaucratic nature of research governance was also discussed; it wasfelt this should be replaced by patient (and participant?) thinking about whatis actually required to protect patients and participants, their interests andrights. Specific criticism was levelled at protective measures seen asdisproportionate to the risks involved – it being argued that you don'tnecessarily need the same processes for a piece of qualitative research asyou do for brain surgery. Thus the Group’s discussion led to consideration ofmany broader issues that lay outside the purview of any single study andunderlined the need for PPI influence at the strategic and policy level. Whileviews may differ on how much that influence is already felt (depending
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probably on the fields or types or research one is most familiar with) therewas consensus in the group that more of it would be to the advantage ofall concerned.
B : A r e t h e p e o p l e e n r o l l e d i n a c l i n i c a l s t u d yb e s t ( o r mo s t a c c u r a t e l y ) d e s c r i b e d a sp a r t i c i p a n t s , c o l l a b o r a t o r s o r r e s e a r c hs u b j e c t s ?
Chair: Dr Brian Balmer (UCL)Introducing the discussion: Dr Oonagh Corrigan (Associate Professor inSociology and Ethics, University of Plymouth)
Dr Brian Balmer, as Chair, introduced the Group’s report. He commented thatdiscussion had shifted from the question of a correct title (collaborators,participants and so on), onto a discussion of why these terms did or notmatter. The Group’s conclusion was that these terms were context­specific,and need to be seen as occupying a range of positions along a spectrum ofhuman agency, with collaborators being the most empowered. The list couldbe extended to include other terms, such as user, partner, healthy volunteer,however all these are equally complex and loaded. They were not able toresolve the issue, only to show the complexity of the terms in discussion.
Dr Balmer gave an instance of ‘why it matters’ and how changing theterminology might have the effect of making the experimenter think about themeaning of participation from the participant’s point of view. The processmay well be different from the point of view of the experimenter than fromthat of the research volunteer. An example could be taken from the work ofSimon Cohn who found that participants perceived by the clinical team aswonderfully altruistic healthy volunteers, themselves cited reasons forparticipation relating to personal health issues. Volunteers from the imagingstudy presented in the morning session, had fully understood that the testthey undertook would be of no personal health benefit. They neverthelessheld the thought that as research (by definition) throws up new things, itmay yield new information which would add to knowledge of their disease orhealth status. Thinking about terminology might encourage thinking aboutassumptions. The group also called attention to the wide diversity ofresearch situations, from relatively harmless procedures to manipulating thetreatment of life­threatening conditions. A broad spectrum of relationshipsand interactions are encompassed between those two extremes. As such, thetitle and contribution of lay­people in research processes is likely to vary. Inaddition, these boundaries may shift throughout any individual study.
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A question arose as to what term could be used for lay people (patients orpublics) involved in policymaking decisions and activities. A corollary was howdoctors tend to categorise all members of ‘the public’ as patients (sinceeveryone is on a GP’s list) but, interestingly, with varying degrees ofabstraction. Comparing the usage of a range of committee members ofmedical professional bodies, there seemed to be a possible correlationbetween presence of substantial lay membership on such bodies and lessabstract, more meaningful talk about ‘patients’. Dr Adrienne Morganrecounted how as a cancer patient involved in a number of clinical trials shehad experienced a number of roles. Through IPCV she had been involved asa collaborator, helping design trials from the outset. On another occasionshe had been a research subject in a huge randomised clinical trial, turningup every so often to have the injection, with very little information. She hadalso been a participant when filling in an annual form once a year about herdiet. But how should she categorise a request from her surgeon to use herlymph node for research ? Would she or her lymph node here be theparticipant?
C : Go v e r nme n t p o l i c y p l a n s t o i n c r e a s e t h ep r o p o r t i o n o f p a t i e n t s t a k i n g p a r t i n r e s e a r c h .Wha t a r e t h e i m p l i c a t i o n s o f t h i s f o r p a t i e n t sa n d r e s e a r c h p a r t i c i p a n t s ?
Chair: Professor Ulf Schmidt (University of Kent)Opening the discussion: Dr Janet Wisely (Director, National Research EthicsService)
Professor Schmidt reported that the group had held a lively discussion, whichhad looked at the politics of research from different perspectives. Theyaddressed issues of information­sharing and transparency, includingcommunication and cooperation between different groups, control of data,and gate­keeping of data for protection of participants. The group had alsodiscussed the market, taking into account that UK policy fully recognisedthat the medical research industry was not just health­creating, but alsowealth­creating, and as such was of great interest to politicians. Finally, theGroup had touched on the following in more detail.
Ethical caution and its consequencesOne of the issues arising in the group was a sense of living in a risk­averseculture, in which people might shy away from research. Not only was ethicalcommittee review given prominence but institutions, funding bodies andresearchers had concerns about legal liability. There was a lot of discussionabout the possibly excessive caution shown by ethics committees over
RE
FLE
CT
ION
S
&
EX
PL
OR
AT
ION
53
approaches to patients about research. One example was whether, havinggiven a patient details of a study, it is reasonable and permissible to follow­up any non­responders to ask if they have decided, and whether precludingsuch approaches constitutes a barrier to these patients becoming part of thetrial (see advice issued by the National Research Ethics Advisors’ PanelNREAP/02 at http://www.nres.npsa.nhs.uk/aboutus/nrea/ which recommendsa more balanced and contextual response).
Who does regulation protect? And issues of trustA member of the Group had raised the issue of whether the framework putin place by the Government protects the patient, or mainly protects the care­giver. This linked to Stuart Blume’s comments on how we havereconceptualised trust. So rather than trust being a relationship that occursbetween individuals, patients and doctors and so on, this definition has beendisplaced by a need on the professionals’ part to prove that they aretrustworthy, and subsequently, much box ticking. As such it is legitimate toask, when a government or any other official body seeks to put a code ofethics in place, just what the functions of that code are. These changes alsomean that people are required to play new sorts of games to get theirresearch projects launched. Added to this was the further bureaucracyassociated with funding, R&D approval from hospital trusts, and a generallack of transparency.
Implications of cultural diversityAnother important issue, which was briefly raised earlier in the day, was thatof cultural, religious or ethnic difference. Knowledge is lacking about howdifferent communities might feel about research participation. This potentialdiversity of viewpoints did not appear to be represented among theparticipants of the workshop.
54
F i n a l W o r k s h o p D i s c u s s i o n
Wha t k i n d o f r e g u l a t i o n ?
A number of contributions focused on the issue of the kind of regulationthat would better fit with current needs, and the linked issue of trust – anessential corollary, but one which, perversely, the system at times tended todisplace. The question was raised as whether self­discipline might bepreferable to systems of largely external, and inevitably bureaucraticregulation. Are we now sufficiently inculcated with ethical ways of thinking togovern ourselves both rigorously and efficiently? Acting as a counter to thiswas the difficulty of judging whether the practice of research was indeedmore or less ethical than before (practice had changed but so had society)and practical considerations as to the sustainability of a self­policing system,given the ‘fade’ effect over time and the constant influx and outflow ofresearchers needing training and mentoring. The general consensus was thatclinical research practice – in terms of thinking about patients’ andparticipants’ needs and about ethics – had changed, but ethics committeeswere still needed to maintain patients’/participants’ trust, and to provide forthe transparency in the system that had frequently been called for duringthe meeting. This was not to endorse the regulatory system as it operatedat present unquestioningly: it does not cover all the patient/participant needsthat had been identified during the workshop and risked promoting onlyformal compliance rather than actual good practice.
P r a c t i c e a n d f u n c t i o n s o f t h e e t h i c s c omm i t t e es y s t em
It was pointed out that only 20% of applications to Ethics Committees got afavourable opinion first off: around 50% got provisional approval. A majorfunction of the committees was to scrutinise how studies were presented toparticipants, rather than suitability of the research design. The NationalResearch Ethics Service saw more scope for trust in the system, and scopefor more limited review for some kinds of studies. Ethic Committees wouldstill provide the important safeguard of an independent assessment of theaccuracy of patient information compared against protocol; they could lookat proposals from the point of view of the participant – something it wasmore difficult for clinicians or researchers to do.
Picking up on the theme of ‘who does the ethics system protect?’ raised byBreak­Out Group C, it was noted that some of the components of thesystem were clearly being used for purposes other than the protection ofparticipants. This applied particularly to Informed Consent, where the formsto be signed were often more like contracts, including waiving any participant
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rights to tissues or intellectual property. This detracted from the clarity ofthe Ethics Committees’ function of serving participants’ interests, and it wassuggested that some separating out might be needed. This was anotherinstance of how the ethical review system needed to adapt its practices tochanging times and social developments.
Go i n g b e y o n d ‘ p r o t e c t i o n ’
Patients and participants wanted information – about the trials they were in,and (increasingly) about trials that were available. Some patients felt stronglythat clinicians tended to be restrictive about access to trials. This they feltwas disadvantageous to patients who were interested in taking part inresearch or desired access to experimental treatments. Various publicly­supported initiatives were mentioned that are developing public informationresources on ongoing and planned trials so that patients might proactivelyseek enrolment in appropriate studies. There was also a public interest inpublishing details of trials that had had negative results or provedinconclusive (as well as potential benefit to other researchers in the field).Funders were said to be increasingly requiring that researchers register theirtrials and register the results. There were international efforts to ensure thatcommercial trials also were similarly registered. Additionally in the UK EthicCommittees would put this question to applicants (including commerciallysponsored trials) and also had adopted the practice of publishing a summaryof the research and the committee’s suggestions, unless good reasons couldbe advanced for delay.
The pressures for access to trials (particularly among activist patient groups)and for more information (a widespread desideratum among both patientsand publics) should not lead to neglect of other, and partly countervailing,patient needs. There were those patients who did not desire participation inresearch, wanted a more conventional doctor­patient relationship andpreferred to trust in the ‘tried and tested’ treatment. There appeared to beincipient conflict between the ‘old’ principle of patient choice, and nationalpolicies and social pressures to enrol in medical research studies. A furtherissue was the inadequacy of the clinical trial formula – particularly in itsrandomised, controlled trial format – to deal satisfactorily with some kinds ofdiseases or conditions (especially those that were long­term or complex, likecomplications from diabetes, or people with mental health problems). Thiswas beginning to be appreciated in policy circles – possibly helped on byappraisal of their high costs and very high proportion of inconclusiveoutcomes. Public, patient and participant influence could help to inform thisdebate or educational process.
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A final wry point made was that we should be wary of patient empowermentbeing used as just another rhetorical device: “It’s something you have toagree with but often in the health domain it means empowering patients todo what we have pre­decided is in their best interests and ours, which looksa lot like disempowerment.”
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CONC L U S I O N & N E X T S T E P S
The variety and richness of discussion at the Workshop made it impossibleto draw together in the final discussion all the insights, observations andproposals for action that had emerged during the course of the day. Withthe advantage of more time, and documentation of the event, the organisershave however highlighted here some of the recurring themes andrecommendations.
The conclusions and discussion from the Workshop are to be furtherdeveloped in the Research Volunteers Forum which has a dedicated website(www.ucl.ac.uk/researchvolunteersforum), where more detailed information onthe proceedings of the Workshop is to be found, including audio podcasts ofall the presentations. The expectation is that individuals and organisationswill have been motivated by these discussions to take up the themes mostappropriate to their sphere, and create more developed plans of action.
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Our general conclusion was that the question of research on (or with)human beings must involve consideration at both the macro and microlevels. Here, macro was understood as the level of the social and political.,including issues of ‘the politics of clinical trials’, the inequalities of powerembedded in social structures, the assumptions and characteristics ofsystems of research governance, and the immense diversity of both clinicalstudies and research participants which made generalisation difficult. Themicro level embraced the experience and expectations of the individualresearch participant (still a relatively under­investigated topic), as well as thescrutiny of individual clinical studies which makes up much of the day­to­daywork of research regulatory systems (via ethics committees), and patient orconsumer liaison groups. The division is of course notional, in practice themicro and the macro are embedded each in the other. The distinctionbecomes useful however when considering matters like the actual orpotential role of public, patient and participant involvement in ameliorating orreforming current policies and practice.
M i c r o l e v e l i s s u e s
Professor Blume, in the conclusion to his address pointed to the need tounderstand issues at the individual level to appreciate the underlying politics:‘In summary: to appreciate the inherently political nature of medical research,we have to understand its meaning for potential volunteers, their assessmentof the likelihood of its benefiting themselves, their children or theircommunity and the ways in which the local political economy of healthshapes the choices available to them.’
C ommen t s a n d r e c ommen d a t i o n s f o r a c t i o n :
1. Steps lying mainly in the purview of patient organisations and partnershipgroups
• Many of those active in public/patient involvement (PPI) felt the lackof any clear pattern for relationships between the PPI groups andparticipants: there was a lack of clarity about roles within the groupsand about what was expected of the different parties involved. Thisneeds to be explicitly addressed.
• PPI activity, following the pattern of regulation and funding forresearch, tends to be front­loaded. This has reduced the capacity ofPPI groups to follow through the complete participant experience and
CONC L U S I O N & N E X T S T E P S
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give attention to matters such as the operation of complaintssystems or participant anxieties. PPI groups need to extend theirinvolvement with individual clinical studies to include these areas.
• Patient groups have been held back from developing direct channelsof communication with research participants because current rules ofconfidentiality deny them access. These rules need to be re­thoughtin order to establish more effective liaisons between patients onManagement Groups and individual participants.
• In some situations, those involved in trial design could alleviate thisproblem by inserting a clause into standard research consent formsthat permits this kind of communication.
• It was widely agreed that giving feedback to research participants onresults and acknowledging their contribution were important steps, butoften omitted. There was scope for encouraging Ethics Committees,professional bodies or umbrella organisations to make observance ofthis courtesy a condition of approval or membership. Approachesshould be made to carry this forward.
2. Steps for increasing understanding of the different meanings of ‘researchparticipation’
It was suggested that better understanding in this area was a key to forgingproductive working relationships between researchers and participants, to thebenefit of both parties. This should include:
• Recognition of the different roles of research participants. Theseoccur along a spectrum of empowerment (ranging roughly from‘research subject’ to ‘collaborator’) and can potentially evolve duringthe course of a project. Participants find themselves situated in ahuge range of research projects from those with a relatively trivialimpact on the volunteer, to others with life and death consequences,and involve participants in differing states of dependency on healthcare.
• Recognition that the participants’ expectations, assumptions andinterpretations of what is going on in the research may be differentfrom those of the researchers.
• Use of a reflection on terminology (subject, collaborator, partner,guinea pig etc) as a framework (a) for researchers to look criticallyat their own practice and question their assumptions aboutvolunteers’ expectations or understandings, and (b) for participants in
60
assessing the quality of their experience and the contribution theywere allowed to make.
Ma c r o l e v e l i s s u e s
In the course of the discussions, the workshop participants identified anumber of general principles or issues they considered of greatestimportance for a sound clinical research system and ensuring a positiveexperience for all participants, in whatever capacity.
TrustTrust was agreed to be crucial but typically depended on matters extendingbeyond the confines of any individual study. It included participants’ generalperceptions of the medical profession, and of the power and motives of thepharmaceutical industry. It framed their questions about whether the processof informed consent was there to protect physicians and health providers orto protect the participants. There was also a delicate relationship betweentrust and regulation. Lack of trust led to demand for more regulation; butadditional regulation might lead to formal compliance only (the tick­boxmentality) and give false reassurance. Recommendations about changes toregulatory systems and bureaucracy (see below) attempted to address thisquestion.
Gaps in regulatory systemOf major concern were the areas not covered by current UK regulatorysystems, the workshop identified two major deficits:
• Current regulatory frameworks focus on participants’ immediatephysical and emotional wellbeing and fail to address important socialissues. These issues include sharing information with participantsthrough regular feedback, availability of treatments post­trial,artificiality of trial conditions, assumptions made about participants’roles, complaints procedures. Patient and participant input could beof crucial importance here.
• There is a lack of attention to the deficiencies of commercial trials inmatters of public involvement and of variable scientific standards. Itwas agreed that this topic needed to move up the public agenda.
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BureaucracyThere was concern at what was perceived as unnecessary or inappropriateregulation. Suggestions for action included:
• Thinking through the whole system afresh starting from whatparticipants/patients need. This radical proposal was well supportedbut could not be extensively developed in the course of the meeting.It has been noted as a key point for follow­up.
• Encouraging NRES to take further their initiatives in matters such asproportionate review, and to review restrictions on access toparticipants or potential participants.
• Continue to improve system transparency.
Knowledge­sharingThe workshop participants addressed the question of knowledge­sharing fromdifferent angles. There was discussion on the sharing of intellectual property,though this was not pursued in depth. At the workshop, the main issuesabout knowledge­sharing concerned the kind of information that is needed tomeet the expectations of proactive patients, patient groups and potentialparticipants. These included:
• Feedback from trial organisers to research participants (as identifiedearlier) and recognition of their contribution to the research andstatus as partners, rather than ‘subjects’.
• Putting information into the public domain about available trials forthose who would be interested in enrolling. Recent progress inmaking such information available was noted but there was still roomfor making it more patient­friendly.
• Availability of information about clinical trials that had negative orinconclusive results. It was emphasised that active patients andpatient groups with an interest in research valued such informationand considered it a benefit, as much as the professional researchcommunity.
• The development of Ethics Committee practice to encourage thesetrends and require publication of summaries of research waswelcomed, and would be followed with interest.
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Patient choiceThree main points for vigilance and policy influence were noted under thisheading:
• Social structural, and national policy influences that could restrictpatient choice will require further debate beyond the workshop. Theseinclude the lack of alternative health care, the blurring of researchand care borders (research as higher quality care), and socialpressures to enrol.
• Physicians’ restrictive or selective approach to eligibility or suitabilityof entrants to clinical trials (or other clinical studies) could beconstrued as limiting patient choice. Addressing these practices wasseen as a high priority by some workshop participants.
• Enthusiasm as to the benefits of research participation or argumentsabout social responsibility still needed to be balanced against theprinciple of individual patient choice.
Expansion of public, patient and participant involvement and influenceThe essential role that could be played by the trio of publics, patients andresearch participants in maximising the benefits of the research system wasa key theme of the meeting. The discussions identified a number of coreissues that need to be addressed, in some cases indicating possible coursesof action, in others identifying the questions as an agenda for the future.
• Extending current mechanisms of PPI (this term to be understood asin practice ‘PPPI’, ie to include a clear research participant voice) intoa wider range of clinical studies. It needs to be more than a nichemarket, yet figures showed that, despite its positive results (for bothresearch and patients), PPI covers only a very small proportion of thetotality of clinical research.
• Extending PPI’s remit further into the strategic field­ to address, inpartnership with other research actors, those issues identified earlier(such as trust, social structures, limitations of regulatory systems)that transcended the bounds of any single study or group of studies.
• Using the public/patient/participant voice at the policy table toarticulate the kinds of research, the kinds of ethical review and thestructures of research governance that met those constituencies’needs.
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• Similarly, for the public/patient/participant voice to join and influencedebates on topical or timely issues. Contemporary examples would bethe differences in practice between public and commercial trials, orthe limitations of the RCT (randomised controlled trial) especially forlong­term and complex conditions.
• Extending public and patient influence and the partnership conceptinto the area of laboratory­based research (which accounts for themajor share of medical research resources).
• Developing robust methods of evaluating the PPI content of researchproposals and benefits of PPI partnerships to help in achieving theabove objectives.
• Among these grand designs, not to lose sight of the costs of runningpartnerships of the type envisaged. These should be budgeted forwithin research proposals and recognised as legitimate by fundingbodies. Publics who cannot count on institutional resources to coverthe costs of their time, carers’ time and travel expenses, should notbe expected to pay the bill themselves, with all the inequities thisimplies.
N e x t S t e p s
The collective conclusions and recommendations from the workshop havedrawn up a formidable agenda for action but say little about ways andmeans. The expectation is that individuals and organisations will have beenmotivated by these discussions to take up the themes most appropriate totheir sphere, and create more developed plans of action. Some themes maybe taken forward through joint action in partnership with contacts made atthe Workshop. The Forum facility on the Research Volunteers website hostedby UCL www.ucl.ac.uk/researchvolunteersforum has been created to provideboth an information resource and a continuing forum for debate andexchange of views.
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G LO S S A R Y O F A C RON YM S
ABPI / Association of the British Pharmaceutical Industry
CBPR / Community­based Participatory Research
CERES / Consumers for Ethics in Research, UK patient advocacy group
DCIS / Ductal Carcinoma In Situ
ICPV / Independent Cancer Patients Voice, UK cancer patient advocacy group
KCL / King's College London
MHRA / Medicines and Healthcare products Regulatory Agency, UK
MRC / Medical Research Council, UK
NCRI / National Cancer Research Institute, UK
NIHR / National Institute for Health Research, UK
NREAP / National Research Ethics Advisors’ Panel, UK
NRES / National Research Ethics Service, UK
PPI / Patient and Public Involvement
ProtecT / Prostate testing for cancer and treatment study, UK
RCT / Randomised Controlled Trials
UCL / University College London
UCLH / University College London Hospital
Booklet Design: Evie Haines / www.eviehaines.org
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Booklet Design: Evie Haines / www.eviehaines.org
Current research strongly suggests that the quality of the relationship betweenthe researcher and the researched subject in biomedics is crucial for theachievement of both volunteer satisfaction and successful and reliable researchoutcomes. The organisers of this Workshop believe that such findings have policyimplications for:
• the design and management of clinical trials and other experimentalbiomedical research using humans
• revisiting the concept of the volunteer that is embedded in researchregulation and ethical codes
• the role of patient advocacy groups
• researcher training
• policy­makers, politicians and executives concerned with strategic priorities
The Workshop provided an opportunity to discuss such issues with a wide rangeof organisational and individual stakeholders in the research enterprise (includingresearchers, patients, patient groups, funders, managers and policy­makers). Theformat of the meeting placed an emphasis on sharing the expertise andperspectives of all participants. Presentations were kept very short, with extendedprovision for break­out groups, debate and networking. Together, thesestakeholders reviewed the scope for joint and individual action and collectivelysuggested ways forward.
Please visit www.ucl.ac.uk/researchvolunteersforum for more information and forpodcasts of the event.
